Related Experiment Video
Updated: Sep 2, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma
Zhicheng Liu1, Dongxu Lin2, Yi Zhou1
1Department of Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Abstract:
The emerging targeted therapies have revolutionized the treatment of advanced clear cell renal cell carcinoma (ccRCC) over the past 15 years. Nevertheless, lack of personalized treatment limits the development of effective clinical guidelines and improvement of patient prognosis. In this study, large-scale genomic profiles from ccRCC cohorts were explored for integrative analysis. A credible method was developed to identify synthetic lethality (SL) pairs and a list of 72 candidate pairs was determined, which might be utilized to selectively eliminate tumors with genetic aberrations using SL partners of specific mutations. Further analysis identified BRD4 and PRKDC as novel medical targets for patients with BAP1 mutations. After mapping these target genes to the comprehensive drug datasets, two agents (BI-2536 and PI-103) were found to have considerable therapeutic potentials in the BAP1 mutant tumors. Overall, our findings provided insight into the overview of ccRCC mutation patterns and offered novel opportunities for improving individualized cancer treatment.
Insights
This study identifies synthetic lethality pairs for clear cell renal cell carcinoma (ccRCC) treatment. Novel targets BRD4 and PRKDC show potential for BAP1-mutated ccRCC, offering new avenues for personalized cancer therapy.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Targeted therapies have advanced clear cell renal cell carcinoma (ccRCC) treatment.
- Personalized treatment strategies are lacking, hindering clinical guidelines and patient outcomes.
- Understanding ccRCC mutation patterns is crucial for developing effective therapies.
Purpose of the Study:
- To explore large-scale genomic profiles of ccRCC cohorts for integrative analysis.
- To identify synthetic lethality (SL) pairs for selective tumor elimination.
- To discover novel therapeutic targets and agents for ccRCC, particularly BAP1-mutated tumors.
Main Methods:
- Integrative analysis of large-scale ccRCC genomic profiles.
- Development of a method to identify synthetic lethality (SL) pairs.
- Identification of novel targets (BRD4, PRKDC) for BAP1-mutated ccRCC.
- Mapping identified targets to drug datasets to assess therapeutic potential.
Main Results:
- A list of 72 candidate synthetic lethality (SL) pairs was identified.
- BRD4 and PRKDC were identified as novel therapeutic targets in BAP1-mutated ccRCC.
- BI-2536 and PI-103 demonstrated therapeutic potential against BAP1-mutant ccRCC.
Conclusions:
- The study provides an overview of ccRCC mutation patterns.
- Novel opportunities for individualized ccRCC treatment were identified.
- Synthetic lethality offers a promising strategy for targeted ccRCC therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...